Table 2.

Association between hyperphosphatemia and the composite outcome (death or progression to ESRD) in the study cohort

VariableOverall (n = 1716)
Age-AdjustedCase Mix ModelaCox Full Modelb
HR95% CIPHR95% CIPHR95% CIP
P < 3.3 mg/dl0.640.42 to 0.960.030.750.49 to 1.140.180.780.51 to 1.190.25
P ≥ 3.3 and < 3.8RefRefRef
P ≥ 3.8 and < 4.31.290.91 to 1.810.140.980.69 to 1.390.940.930.66 to 1.330.72
P ≥ 4.34.012.93 to 5.47<0.0012.321.64 to 3.27<0.0012.041.44 to 2.90<0.001
  • a Case mix: age + gender, eGFR, history of diabetes mellitus, history of hypertension, and history of COPD and CVD.

  • b Full model: age + case mix + hemoglobin, total calcium, uric acid and ACE inhibitors, vitamin D, and calcium salts use.